Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Uvax Bio Appoints Kevin O'neill As Interim Chief Executive Officer (CEO)

PRIVATEFeb 04, 2025•over 1 year ago

Position

Chief Business Officer

Company

Uvax Bio

Kevin O'Neill

NewarkBiotechnologyHealth CareTherapeutics

Description

Uvax Bio, LLC has announced the appointment of Kevin O'Neill as Interim Chief Executive Officer (CEO). Mr. O'Neill succeeds Ji Li, Ph.D

Company Information

Company

Uvax Bio

Location

Newark, Delaware, United States

About

Uvax Bio, LLC is a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines. The company holds exclusive worldwide rights to the 1c-SApNP® platform and has an expanding portfolio of two clinical and 10 patented preclinical vaccine candidates.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Uvax Bio's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months